Payment overview · 2025
General Payments
$355.24
21 reported records · 6 companies
Healthcare provider profile · identity verified
Christopher Donovan Beckett, DO
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · WILLIAMSON, WV · NPI 1174575898
Verified facts
What the public records show
CMS Open Payments records show Christopher Donovan Beckett, DO received $355.24 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 50.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $180.04 | 50.7% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.51 | 15.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.87 | 11.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.53 | 10.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.08 | 8.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.21 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.24 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $158.74 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 217 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1071 | 137 |
| Gabapentin | Gabapentin | 787 | 122 |
| Clonazepam | Clonazepam | 617 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 117 |
| Lisinopril | Lisinopril | 481 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 435 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 427 | 103 |
| Alprazolam | Alprazolam | 390 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 103 |
| Metformin Hcl | Metformin Hcl | 364 | 95 |
| Omeprazole | Omeprazole | 350 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 79 |
| Furosemide | Furosemide | 250 | 75 |
| Azithromycin | Azithromycin | 242 | 151 |
| Zolpidem Tartrate | Zolpidem Tartrate | 228 | 27 |
| Ozempic | Semaglutide | 217 | 40 |
| Tramadol Hcl | Tramadol Hcl | 217 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 55 |
| Montelukast Sodium | Montelukast Sodium | 191 | 51 |
| Testosterone Cypionate | Testosterone Cypionate | 179 | 35 |
| Carvedilol | Carvedilol | 178 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 36 |
| Losartan Potassium | Losartan Potassium | 169 | 45 |
| Potassium Chloride | Potassium Chloride | 169 | 46 |
| Trazodone Hcl | Trazodone Hcl | 167 | 53 |
| Simvastatin | Simvastatin | 163 | 51 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 144 | 88 |
| Fluoxetine Hcl | Fluoxetine Hcl | 144 | 38 |
| Meloxicam | Meloxicam | 135 | 42 |
| Ibuprofen | Ibuprofen | 124 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 121 | 51 |
| Mounjaro | Tirzepatide | 119 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 47 |
| Lorazepam | Lorazepam | 110 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 23 |
| Sertraline Hcl | Sertraline Hcl | 107 | 29 |
| Diazepam | Diazepam | 106 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 105 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 41 |
| Allopurinol | Allopurinol | 98 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 27 |
| Eliquis | Apixaban | 93 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 91 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 32 |
| Pregabalin | Pregabalin | 87 | 18 |
| Levofloxacin | Levofloxacin | 81 | 51 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 69 | 30 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 69 | 18 |
| Glipizide | Glipizide | 67 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 17 |
| Atenolol | Atenolol | 63 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 15 |
| Bupropion Xl | Bupropion Hcl | 61 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 16 |
| Novolog Flexpen | Insulin Aspart | 60 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 59 | suppressed |
| Vascepa | Icosapent Ethyl | 59 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Donepezil Hcl | Donepezil Hcl | 56 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 17 |
| Fluconazole | Fluconazole | 53 | 26 |
| Meclizine Hcl | Meclizine Hcl | 53 | 23 |
| Methylprednisolone | Methylprednisolone | 53 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 15 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Baclofen | Baclofen | 49 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 49 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 14 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Famotidine | Famotidine | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Ezetimibe | Ezetimibe | 45 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 15 |
| Ramipril | Ramipril | 45 | 12 |
| Topiramate | Topiramate | 45 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 13 |
| Fenofibrate | Fenofibrate | 41 | 13 |
| Prednisone | Prednisone | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Linzess | Linaclotide | 33 | 11 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Amoxicillin | Amoxicillin | 27 | suppressed |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 15 |
| Estradiol | Estradiol | 24 | suppressed |
| Ibu | Ibuprofen | 24 | 12 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Temazepam | Temazepam | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Finasteride | Finasteride | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.24 · 21 records | Novo Nordisk Inc | EVENITY, FREESTYLE LIBRE 2, Kerendia, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error